RedHill Biopharma (Israel) Management Performance Evaluation

RDHL -- Israel Stock  

ILS 258.40  3.60  1.37%

Analysis of RedHill Biopharma manpower and management performance can provide insight into RedHill Biopharma stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with RedHill Biopharma future performance. Additionally take a look at Your Equity Center.

RedHill Biopharma Management Effectiveness

The company has return on total asset (ROA) of (51.61) % which means that it has lost $51.61 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (112.59) % meaning that it generated substantial loss on money invested by shareholders.

RedHill Biopharma Workforce Comparison

RedHill Biopharma Ltd is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is at this time estimated at about 1,326. RedHill Biopharma holds roughly 74.0 in number of employees claiming about 6% of stocks in Biotechnology industry.

RedHill Biopharma Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of thirty-nine. RedHill Biopharma Price Series Summation is a cross summation of RedHill Biopharma price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

RedHill Biopharma Stakeholders

Ori Shilo Co-Founder and Deputy CEO of Fin. and Operations
Dror BenAsher Chairman of the Board, CEO
Patricia Anderson Vice President - Regulatory Affairs
Aida Bibliowicz Vice President - Clinical Affairs Europe
Adi Frish Senior Vice President - Business Development and Licensing
Tom Lang Vice President - Regulatory & Clinical Affairs
Gilead Raday Senior Vice President - Product and Corporate Development
Shani Maurice Vice President - Business Development & Communications
Micha Chorin CFO
Reza Fathi Sr. VP of RandD
Ofer Tsimchi Director
Shmuel Cabilly Director
Kenneth Reed Director
Pascal Weerts Director - Corporate and Legal Affairs
Eric Swenden Director
Dan Suesskind Director
Rick Scruggs Director
Terry Plasse Medical Director
Danielle Abramson Director - Intellectual Property & Research
Ira Kalfus Medical Director
Nurit Benjamini External Director
Patrick Mclean Product Manager
Elkan Gamzu Product Manager
Guy Goldberg Chief Business Officer
Clara Fehrmann Product Manager
Uri Aharon Chief Accounting Officer
Patricia Bandeira Product Manager - Oncology

RedHill Biopharma Leadership

RedHill Biopharma Top Executives

  Ori Shilo  CEO
Co-Founder and Deputy CEO of Fin. and Operations
  Dror BenAsher  Chairman
Chairman of the Board, CEO

RedHill Biopharma Tenure Analysis

RedHill Biopharma Employment Tenure

RedHill Biopharma employes about 74 people. The company is managed by 27 executives with total tenure of roughly 113 years, averanging almost 4.0 years of service per executive having 2.0 employee per reported executive.

RedHill Biopharma Manpower Efficiency

Return on RedHill Biopharma Manpower

Revenue Per Employee121.6 K
Revenue Per Executive333.3 K
Net Loss Per Employee561.5 K
Net Loss Per Executive1.5 M
Working Capital Per Employee662.2 K
Working Capital Per Executive1.8 M
Additionally take a look at Your Equity Center. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Search macroaxis.com